DCIS recurrence and invasive breast cancer
AssigneePrelude Corporation
InventorsTroy M. Bremer, Steven Paul Linke
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.
Claims28
A method for treating a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the DCIS sample for at least:
- PR, HER2, and SIAH2 expression levels, and patient menopausal status by measuring presence/absence and/or measuring expression levels of PR, HER2, SIAH2, and obtaining menopausal status;
- or
- PR, HER2, and SIAH2 expression levels by measuring presence/absence and/or measuring expression levels of PR, HER2, and SIAH2,
- wherein the analyzed DCIS sample is determined to be at least:
- PR−, HER2−, and SIAH2−;
- or
- PR−, HER2−, SIAH2−, and pre-menopausal;
- and
- based on determining that the DCIS sample is (1) PR−, HER2−, and SIAH2−, or (2) PR−, HER2−, SIAH2−, and pre-menopausal, treating the subject with at least one of:
- adjuvant radiation;
- or
- endocrine therapy,
- thereby reducing the subject's risk of subsequent ipsilateral invasive breast cancer.
A method for recommending and providing a treatment to a subject, said method comprising:
- receiving a DCIS sample from a subject;
- analyzing the DCIS sample for at least:
- PR, HER2, and SIAH2 expression levels, and patient menopausal status by measuring presence/absence and/or measuring expression levels of PR, HER2, SIAH2, and obtaining menopausal status;
- or
- PR, HER2, and SIAH2 expression levels by measuring presence/absence and/or measuring expression levels of PR, HER2, SIAH2,
- wherein the analyzed DCIS sample is determined to be at least:
- PR−, HER2−, and SIAH2−;
- or
- PR−, HER2−, SIAH2−, and pre-menopausal;
- based on determining that the DCIS sample is (1) PR−, HER2−, and SIAH2−, or (2) PR−, HER2−, SIAH2−, and pre-menopausal, recommending at least one of the following treatments:
- adjuvant radiation;
- or
- endocrine therapy;
- and
- administering the recommended treatment to the subject, thereby reducing the subject's risk of subsequent ipsilateral invasive breast cancer.
A method of reducing a risk of subsequent ipsilateral invasive breast cancer in a subject having DCIS, said method comprising:
- providing a DCIS sample from the subject;
- determining that the DCIS sample is at least:
- PR−, HER2−, and SIAH2−;
- or
- PR−, HER2−, SIAH2−, and pre-menopausal
- based on determining that the DCIS sample is (1) PR−, HER2−, and SIAH2−, or (2) PR−, HER2−, SIAH2−, and pre-menopausal, the subject receiving adjuvant radiation or endocrine therapy for treatment of the DCIS, thereby reducing a risk of subsequent ipsilateral invasive breast cancer.
Dependencies are inferred from the claim text.